's largest bromide production enterprises will be generated in the

's largest bromide production enterprises will be generated in the extraction of bromine sewage directly discharged down Xiaoguanzhuang ditch into the sea, local villagers said. Media on the matter to an interview with the local environmental protection bureau, the staff is not only the default and this performance was "quite calm", while a staff member Beverly Pharmaceutical further stressed: "bromine enterprises such emissions." In Beverly drugs industry pollution problems on the same day, the well-known North China Pharmaceutical Group under the fold Limited antibiotic residue directly dumping to Hutuo exposure. Why pharmaceutical companies have moral pollution problems before the fall "First Financial Daily" interview, the people in the industry, said companies can not afford the large environmental investment, and the cost of illegal is too low, causing many companies prefer to be punished, do not want to rectification. Public data shows, in Shouguang Fukang Pharmaceutical Co., Ltd. is a high-tech enterprises in Shandong Province, is currently the world's largest TMP raw material drug production and export enterprises, the country's largest bromide production base, the its bromopropane bromochloropropane production in the nation the first place. It is understood that the pharmaceutical and organic intermediates required for bromine chemicals market in recent years been very active, particularly in the export market is more bullish, used to synthesis of new drugs such as fluconazole and diclofenac sodium 2.4-difluoro-bromobenzene, o-bromo phenylacetic acid, etc. pharmaceutical intermediates. Fukang Pharmaceutical Company, was established in 1993, Fukang Pharmaceutical Fukang Pharmaceutical, chemical, Beverly, Ruikang refined, Beverly animal medicine, Yongkang, chemical, Beverly system bromine 12 manufacturing enterprises, mainly engaged in bulk drugs, pharmaceutical intermediates, bromide, thermal dye biopharmaceutical five series more than 60 varieties of the development, production and sales, more than 70 percent of products exported, sold in the United States, Germany, Britain, Switzerland, Japan, South Korea, 60 countries and regions. Query recent data show that after the reform in 2000, for five consecutive years, the economic benefits of Fukang Pharmaceutical doubling 2006 sales revenue of 1.09 billion yuan, profits and taxes 210 million yuan; 2007 sales revenue is expected to exceed 1.3 billion yuan, profits and taxes 2.7 billion. Such as surging and high profits, Fukang Pharmaceutical has enjoyed a "green light" in the local sewage. Local in Shouguang Fukang Pharmaceutical is not only a high-tech enterprises in Shandong Province, system certification, ISO9001, ISO14001, OHSAS18001, the trademark was "Shandong Famous Brand", won the title of the Shandong Province famous brand products and other products; and Shouguang City in 2007 founded as the "National Environmental Protection Model City". Pollution problems of the Chinese raw material drug production for a long time in June 11, 2011, in Beijing on behalf of the enterprise, director of Harbin Pharmaceutical Factory Wu Zhijun apologized to the public recognition of the excessive discharge "caused great harm to the majority of consumer psychology, on the enterprise perimeter the lives of the residents had a negative impact and cause irreparable loss, but also on the reputation and image. Shortly thereafter, the CSPC and federal pharmaceutical domestic pollution problems of key raw material drug production enterprises have been exposed by the media. Why well-known enterprises have the moral fall in front of the pollution problem "the most direct reason is that environmental investment is too great." China Pharmaceutical Industry Association, vice president of Pan Guangcheng on this topic in an interview when he said, "because of all manufacturers numerous varieties of different products related to different environmental standards, the cost of inputs is not a small number. exposure to pollution problems Harbin Pharmaceutical, Harbin Pharmaceutical shares in the bulletin said, "In recent years, the company has invested a total of 400 million yuan for the clean production and environmental governance, mainly the construction of the wastewater pretreatment and wastewater treatment, odor, boiler flue gas, noise and other pollution treatment facilities. annual running costs of the environmental protection facilities in more than 5,000 million. "As for the off-site relocation of investment to eradicate the problem of pollution, Hayao had pessimistically in its 2010 annual report said that due to the off-site plant a huge investment, the value of the products of pharmaceutical raw materials, and profit margins thin, expected to put into operation two or three years will not have a competitive advantage, so can easily result in the business at a loss situation, caused by the enterprises can not survive the consequences. " China Pharmaceutical Enterprises Management Association, told reporters at Matilda, different from the ordinary chemical plant, the raw material drug production areas, a pharmaceutical companies often have to produce dozens of pharmaceutical raw materials, waste composition is completely different, so during the bio-fermentation, using flora is different, and this increases the difficulty of waste disposal of the API manufacturer, coupled with input costs is too large, low-cost illegal, to make this for many years ills become the industry 'problem' would rather be fined, do not want to rectification ". He said. (Source: First Financial Daily)